Clinical overview of fibromyalgia

American Journal of Therapeutics

Volumn 19, Issue 5, 2012, Pages 357-368

  McCarberg, Bill H ^a  

^a Chronic Pain Management Program   (United States)

Author keywords

chronic pain; diagnosis; fibromyalgia; treatment

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CORTICOSTEROID; DULOXETINE; MILNACIPRAN; OPIATE; PARACETAMOL; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL;

AEROBIC EXERCISE; ATTENTION DISTURBANCE; BLURRED VISION; CHRONIC PAIN; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; COST OF ILLNESS; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC ACCURACY; DIZZINESS; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG INDICATION; EDEMA; ENVIRONMENTAL FACTOR; FATIGUE; FIBROMYALGIA; HEALTH INSURANCE; HEART PALPITATION; HEART RATE; HEREDITY; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; IRRITABLE COLON; MUSCLE STIFFNESS; NAUSEA; PATHOPHYSIOLOGY; PATIENT EDUCATION; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; THOUGHT DISORDER; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; FEMALE; FIBROMYALGIA; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; PATIENT COMPLIANCE; POLYPHARMACY; SEX FACTORS;

EID: 84866362985     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181ff7bee     Document Type: Review

References (99)

1. Wolfe F. Fibromyalgia wars. J Rheumatol. 2009;36:671-678.
2. Harth M, Nielson W. War is over. Give peace a chance (with apologies to the late John Lennon). J Rheumatol. 2009;36:2837-2838.
3. Bennett RM. Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin North Am. 2009;35:215-232.
4. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
5. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73:114-120.
6. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol. 2005;32(Suppl 72):6-21.
7. Goldenberg DL. Office management of fibromyalgia. Rheum Dis Clin North Am. 2002;28:437-446.
8. McCarberg BH. Fibromyalgia management for the primary care provider. In: McCarberg BH, Clauw DJ, eds. Fibromyalgia. New York, NY: Informa Healthcare; 2009.
9. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep. 2001;5:320-329.
10. Nielsen LA, Henriksson KG. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition. Best Pract Res Clin Rheumatol. 2007;21: 465-480.
11. Wolfe F. The epidemiology of fibromyalgia. J Musculoskelet Pain. 1993;1:137-148.
12. White KP, Speechley M, Harth M, et al. Fibromyalgia in rheumatology practice: a survey of Canadian rheumatologists. J Rheumatol. 1995;22:722-726.
13. Bennett RM. Rational management of fibromyalgia. Rheum Dis Clin North Am. 2002;28:xiii-xv.
14. White LA, Robinson RL, Yu AP, et al. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain. 2009;10: 976-983.
15. Berger A, Sadosky A, Dukes EM, et al. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care. 2010;16: S126-S137.
16. Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol. 2003;30:1318-1325.
17. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61:1498-1508.
18. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med. 2008;50:13-24.
19. Kleinman N, Harnett J, Melkonian A, et al. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med. 2009;51:1384-1393.
20. Silverman S, Dukes EM, Johnston SS, et al. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin. 2009;25:829-840.
21. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-2395.
22. Burckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. Glenview, IL: American Pain Society; 2005.
23. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536-541.
24. Bradley LA. Pathophysiology of fibromyalgia. Am J Med. 2009;122(Suppl 12A):S22-S30.
25. Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthr Res Ther. 2006;8:208.
26. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895-926.
27. Renn CL, Dorsey SG. The physiology and processing of pain: a review. AACN Clin Iss. 2005;16:277-290.
28. Stahl SM. Fibromyalgia-pathways and neurotransmitters. Hum Psychopharmacol. 2009;24(Suppl 1):S11-S17.
29. Russell IJ, Vaeroy H, Javors M, et al. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550-556.
30. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593-1601.
31. Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3Himipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol. 1992;19:104-109.
32. Yunus MB, Dailey JW, Aldag JC, et al. Plasma and urinary catecholamines in primary fibromyalgia: a controlled study. J Rheumatol. 1992;19:95-97.
33. Yunus MB, Dailey JW, Aldag JC, et al. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol. 1992;19:90-94.
34. Legangneux E, Mora JJ, Spreux-Varoquaux O, et al. Cerebrospinal fluid biogenic amine metabolites, plasmarich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatol. 2001;40: 290-296.
35. Nebel MB, Gracely RH. Neuroimaging of fibromyalgia. Rheum Dis Clin North Am. 2009;35:313-327.
36. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum Psychopharmacol. 2009;24(Suppl 1):S19-S23.
37. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004;19(Suppl 1):S15-S19.
38. Mease PJ. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med. 2009;122(Suppl 12A):S44-S55.
39. Rao SG. Current progress in the pharmacological therapy of fibromyalgia. Expert Opin Investig Drugs. 2009;18: 1479-1493.
40. Clauw DJ. Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry. 2008;69(Suppl 2):25-29.
41. Marangell LB, Clauw DJ, Choy E, et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine. Pain, in press.
42. Gendreau MR, Clauw DJ, Palmer RH, et al. Efficacy of milnacipran in the treatment of fibromyalgia among patients with varying degrees of depressed mood [poster presentation]. Presented at: The 161st Annual Meeting of the American Psychiatric Association; Washington, DC: May 3-8, 2008.
43. Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia-a review. Joint Bone Spine. 2008;75:273-279.
44. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics. 2007;8:67-74.
45. Buskila D. Genetics of chronic pain states. Best Pract Res Clin Rheumatol. 2007;21:535-547.
46. Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain. 2009;10:777-791.
47. Harris RE, Clauw DJ. Newer treatments for fibromyalgia syndrome. Ther Clin Risk Manag. 2008;4:1331-1342.
48. Clauw DJ. Fibromyalgia: an overview. Am J Med. 2009; 122(Suppl 12A):S3-S13.
49. Hudson JI, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am. 1996;22:285-303.
50. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics. 1999;40:57-63.
51. Nease DE Jr, Maloin JM. Depression screening: a practical strategy. J Fam Pract. 2003;52:118-124.
52. Kool MB, van Middendorp H, Boeije HR, et al. Understanding the lack of understanding: invalidation from the perspective of the patient with fibromyalgia. Arthritis Rheum. 2009;61:1650-1656.
53. National Fibromyalgia Association. Available at: http://www.fmaware.org. Accessed August 15, 2010.
54. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17:685-701.
55. White KP, Nielson WR, Harth M, et al. Does the label " fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002;47:260-265.
56. Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58:895-902.
57. Rivera J, Rejas J, Esteve-Vives J, et al. Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain. Clin Exp Rheumatol. 2009;27:S39-S45.
58. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
59. Goldenberg DL. Diagnosis and differential diagnosis of fibromyalgia. Am J Med. 2009;122(Suppl 12A):S14-S21.
60. Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am. 2002;28:181-199.
61. Wolfe F, Ross K, Anderson J, et al. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22:151-156.
62. Marcus DA. Fibromyalgia: diagnosis and treatment options. Gend Med. 2009;6(Suppl 2):139-151.
63. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600-610.
64. Yunus MB. A comprehensive medical evaluation of patients with fibromyalgia syndrome. Rheum Dis Clin North Am. 2002;28:201-217.
65. Shir Y, Fitzcharles MA. Should rheumatologists retain ownership of fibromyalgia? J Rheumatol. 2009;36:667-670.
66. Buskila D, Neumann L, Sibirski D, et al. Awareness of diagnostic and clinical features of fibromyalgia among family physicians. Fam Pract. 1997;14:238-241.
67. Shleyfer E, Jotkowitz A, Karmon A, et al. Accuracy of the diagnosis of fibromyalgia by family physicians: is the pendulum shifting? J Rheumatol. 2009;36:170-173.
68. Mease P, Buskila D, Sarzi-Puttini P. The fibromyalgia conundrum. Clin Exp Rheumatol. 2009;27(Suppl 56): S2-S4.
69. Sewitch MJ, Dobkin PL, Bernatsky S, et al. Medication non-adherence in women with fibromyalgia. Rheumatol. 2004;43:648-654.
70. Dobkin PL, Sita A, Sewitch MJ. Predictors of adherence to treatment in women with fibromyalgia. Clin J Pain. 2006; 22:286-294.
71. Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthr Res Ther. 2006;8:212.
72. Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome-a systematic review. Eur J Pain. 2010;14:5-10.
73. Lyrica [package insert]. New York, NY: Pfizer Inc; 2010. Available at: www.lyrica.com. Accessed August 15, 2010.
74. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2010. Available at: www.cymbalta.com. Accessed August 15, 2010.
75. Savella [package insert]. St. Louis, MO: Forest Laboratories, Inc.; 2010. Available at: www.savella.com. Accessed August 15, 2010.
76. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805-1815.
77. Arnold LM. Strategies for managing fibromyalgia. Am J Med. 2009;122(Suppl 12A):S31-S43.
78. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol. 2005;32:2270-2277.
79. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol. 2007;34:1415-1425.
80. Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009;36:2318-2329.
81. Arnold LM. Advances in the management of fibromyalgia. CNS Spectr. 2009;14:12-16.
82. King T, Gardell LR, Wang R, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005;116:276-288.
83. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain. 2006;7:43-48.
84. Mease PJ, Seymour K. Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy? Curr Pain Headache Rep. 2008;12:399-405.
85. FarmerMV, Dayani N, Trugman JM, et al. Effect of adding milnacipran to pregabalin in the management of fibromyalgia: a randomized, open-label, controlled study [abstract]. J Pain. 2010;11(Suppl 1):S17.
86. Busch AJ, Barber KA, Overend TJ, et al. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev. 2007;4:CD003786.
87. Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am. 2009;35: 393-407.
88. Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol. 2006;2:416-424.
89. Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol. 2009;5:191-199.
90. National Association of State Mental Health Program Directors (NASMHPD). Technical report on psychiatric polypharmacy. Available at: http://www.nasmhpd. org/general-files/publications/med-directors-pubs/polypharmacy.pdf. Accessed August 15, 2010.
91. The Joint Commission Perspectives on Patient Safety. Psychiatric polypharmacy: identifying risks and seeking solutions. Jt Comm J Qual Patient Saf. 2008;8:8-13.
92. Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13:97-105.
93. Preskorn SH. 2010 guide to psychiatric drug interactions. Prim Psychiatry. 2010;161:45-74.
94. D'Arcy Y, McCarberg B. Field guide to pain part 2. Developing a plan of care. Nurse Pract. 2005;30:60-62.
95. McCarberg B, Stanos S. Key patient assessment tools and treatment strategies for pain management. Pain Pract. 2008;8:423-432.
96. Marcus DA. Chronic Pain: A Primary Care Guide to Practical Management. 2nd ed. New York, NY: Humana Press; 2009.
97. Bennett RM, Friend R, Jones KD, et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11: R120.
98. Navarro RP. Contemporary management strategies for fibromyalgia. Am J Manag Care. 2009;15(Suppl 6): S197-S218.
99. American Pain Foundation. Insurance barriers to fibromyalgia care: the national experience. Available at: www. painfoundation.org/learn/publications/ files/insurancebarriers. pdf. Accessed August 15, 2010.